Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:CRY

CryoLife (CRY) Stock Price, News & Analysis

CryoLife logo

About CryoLife Stock (NYSE:CRY)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$17.19
$21.72
52-Week Range
N/A
Volume
7,792 shs
Average Volume
198,221 shs
Market Capitalization
$703.22 million
P/E Ratio
596.20
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CryoLife, Inc. engages in the manufacture, process and distribution of medical devices and implantable human tissues. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue products, aortic stents and stent grafts, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment focuses on revenues from preservation of cardiac and vascular implantable human tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Remove Ads
Receive CRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CryoLife and its competitors with MarketBeat's FREE daily newsletter.

CRY Stock News Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
Artivion price target raised to $35 from $32 at Lake Street
Artivion (AORT) Receives a Buy from Lake Street
See More Headlines

CRY Stock Analysis - Frequently Asked Questions

CryoLife, Inc. (NYSE:CRY) released its earnings results on Thursday, November, 4th. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of $0.04 by $0.22. The medical equipment provider earned $72.21 million during the quarter, compared to analysts' expectations of $72.90 million. CryoLife had a net margin of 0.63% and a trailing twelve-month return on equity of 4.24%.

CryoLife subsidiaries include JOTEC AG, On-X Life Technologies Inc., Hemosphere, Cardiogenesis Corporation, AuraZyme Pharmaceuticals Inc., CryoLife Asia Pacific PTE. Ltd., CryoLife Canada Inc., and others.

Based on aggregate information from My MarketBeat watchlists, some other companies that CryoLife investors own include Energy Transfer (ET), Johnson & Johnson (JNJ), AT&T (T), Meta Platforms (META), Gilead Sciences (GILD), International Business Machines (IBM) and Netflix (NFLX).

Company Calendar

Last Earnings
11/04/2021
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:CRY
Employees
1,200
Year Founded
1984

Profitability

Trailing P/E Ratio
596.20
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,680,000.00
Pretax Margin
0.41%

Debt

Sales & Book Value

Annual Sales
$253.23 million
Price / Cash Flow
23.30
Book Value
$8.46 per share
Price / Book
N/A

Miscellaneous

Free Float
37,560,000
Market Cap
$703.22 million
Optionable
Optionable
Beta
1.53

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NYSE:CRY) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners